You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Colorectal cancer

Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer

  • Technology appraisal guidance
  • Reference number: TA61
  • Published:  27 May 2003
  • Guidance
  • Tools and resources
  • Information for the public
  • History
Download guidance (PDF)
  • Overview
  • 1 Recommendations
  • 2 Clinical need and practice
  • 3 The technology
  • 4 Evidence and interpretation
  • 5 Further research
  • 6 Implications for the NHS
  • 7 Implementation and audit
  • 8 Appraisal committee members
  • 9 Sources of evidence considered by the committee
  • 10 Detail on criteria for audit of the use of capecitabine and tegafur with uracil for metastatic colorectal cancer
  • Update information

5 Further research

5.1

Further research is required to determine the place of capecitabine and tegafur with uracil in the treatment of metastatic colorectal cancer. In particular, RCTs are needed to assess the use of these oral treatments compared with infusional 5-FU/FA regimens. Such studies should include evaluations of quality of life, acceptability and cost effectiveness.


Next page 6 Implications for the NHS Previous page 4 Evidence and interpretation
Back to top